Step by Step

INTRODUCTION

ABIM MOC Activity ID

5/21/2019 - Medical Grand Rounds: Bench to Bedside - Therapeutic Antibodies: from Horses to CARs and CAR T-cell therapy for solid tumors

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:  

  • Describe engineered antibody domains (eAds) as candidate therapeutics.
  • Recognize the importance of the epitope for the efficacy of CAR T cell therapy.
  • Define the ideal characteristics of an antigen target for adaptive T cell therapy.
  • Identify the specific barriers for solid tumor adaptive cell therapy.
  • Recognize the potential benefits of regional delivery of CAR T cell therapy.

Suggested Additional Reading:

  1. Zhu Z et al J Virol 2006, Proc Natl Acad Sci 2007, J Inf Dis 2008
  2. Bishop K et al J Virol 2008; Bossart K et al 2008 Virology, PLoS Pathogens 2009
  3. Xiao X et al PLoS One 2010; Bossart K et al Sci Transl Med 2011
  4. Zhu Z et al Virol Sinica 2013
  5. Ying T et al J Virol 2014
  6. Geisbert T et al Sci Transl Med 2014
  7. Ying T et al Nat Commun 2015
  8. Houser KV et J Infect Dis 2016
  9. Agrawal AS et al Sci Rep 2016
  10. von Doremalen N et al Antiviral Res 2017
  11. Yu F et al Cell Host Microbe 2017
  12. Zhang MY et al J Immunol Meth 2003
  13. Zhu Z and Dimitrov DS Meth Mol Biol 2009
  14. Glennie MJ and Johnson PWM, Immun Today 2001

Authors:
Dimiter Dimitrov, PhD — Professor of Medicine, Division of Infectious Diseases, Director, Center for Antibody Therapeutics, University of Pittsburgh
No relationships with industry relevant to the content of this educational activity have been disclosed.
Prasad Adusumilli, MD, FACS, FCCP — Deputy Chief and Attending (Tenured), Thoracic Surgery, Director, Mesothelioma Program, Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center
Dr. Adusumilli receives a potential royalty from licensing of Mesothelin CAR.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.